title: 5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(beta-hydroxyethyl)-rutosides: a prospective comparative clinical registry.
abstract: This independent prospective controlled trial evaluates the efficacy of O-(beta-hydroxyethyl)-rutosides (HR) during 5 years of administration against signs and symptoms and further degeneration of microcirculatory disturbances. The protective effect of HR in preventing end-point complications such as venous ulceration is evaluated. This study is based on evaluation of edema and the capillary filtration rate (CFR) in association with a clinical score scale. Patients having a severe degree of chronic venous insufficiency (CVI) and venous microangiopathy and completing at least 5 years of treatment are included. The following 4 groups are considered: group A (patients with CVI but without diabetes mellitus, receiving 1500 mg/d of HR), group B (patients with CVI and diabetes mellitus, receiving 2 g/d of HR), group C (control subjects receiving no pharmacologic or compression treatment), and group D (patients using elastic compression stockings only). All patients received the "best" available treatment. No adverse effects or intolerance is noted, with good compliance (>85%). In group A, there is a statistically significant decrease in the CFR during 5 years of follow-up. In group B, the decrease in the CFR is greater than that in group A. Reductions in edema, swelling, and the CFR during 5 years are notable, and values approach normal levels. During 5 years, HR is effective in treating venous edema and hypertension and in preventing deterioration of the distal venous system. The prevention of ulcerations with HR is another important observation. The effects of HR seem to be partially dose related, and tolerability and compliance are good.
authors.affiliation: Department of Biomedical Sciences, Chieti-Pescara University, and the San Valentino Vascular Screening Project, Italy. Cardres@abol.it
authors.forename: Gianni
authors.initials: G
authors.lastname: Belcaro
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Cesarone
authors.forename: Andrea
authors.initials: A
authors.lastname: Ledda
authors.forename: Marisa
authors.initials: M
authors.lastname: Cacchio
authors.forename: Irma
authors.initials: I
authors.lastname: Ruffini
authors.forename: Andrea
authors.initials: A
authors.lastname: Ricci
authors.forename: Edmondo
authors.initials: E
authors.lastname: Ippolito
authors.forename: Andrea
authors.initials: A
authors.lastname: Di Renzo
authors.forename: Mark
authors.initials: M
authors.lastname: Dugall
authors.forename: Marcello
authors.initials: M
authors.lastname: Corsi
authors.forename: Anna Rita
authors.initials: AR
authors.lastname: Marino Santarelli
authors.forename: Maria Giovanna
authors.initials: MG
authors.lastname: Grossi
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001783:Blood Flow Velocity; D001785:Blood Gas Monitoring, Transcutaneous; D002199:Capillary Permeability / Q000187:drug effects*; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D003925:Diabetic Angiopathies / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004487:Edema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D006896:Hydroxyethylrutoside / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017078:Laser-Doppler Flowmetry; D008875:Middle Aged; D010349:Patient Compliance; D011446:Prospective Studies; D012042:Registries; D012720:Severity of Illness Index; D012867:Skin / Q000098:blood supply; D053828:Stockings, Compression; D013997:Time Factors; D016896:Treatment Outcome; D014689:Venous Insufficiency / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D014690:Venous Pressure / Q000187:drug effects
chemical_list: D002317:Cardiovascular Agents; D006896:Hydroxyethylrutoside; C005865:troxerutin